AI-generated analysis. Always verify with the original filing.
Omeros Corporation reported Q4 and full-year 2025 financial results, including $86.5 million Q4 net income driven by $237.6 million zaltenibart transaction gain with Novo Nordisk, FDA approval of YARTEMLEA, and strengthened balance sheet with $171.8 million cash.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events
| Metric | Value | Basis |
|---|---|---|
| Net Income | $86.50 | GAAP |
| Net Income per Share | $1.22 | GAAP |
| Net Income | $-3.40 | GAAP |
| Net Income per Share | $-0.05 | GAAP |
| Non-GAAP Adjusted Net Income | $222.50 | Non-GAAP |
| Non-GAAP Adjusted Net Income per Share | $3.14 | Non-GAAP |
| Non-GAAP Adjusted Net Income | $133.40 | Non-GAAP |
| Non-GAAP Adjusted Net Income per Share | $2.10 | Non-GAAP |
| OMIDRIA Royalties | $9.20 |
Debt / Financing